Gastrointestinal Drugs Global Market Sees Growth Rate Of 9% Through 2026

The global gastrointestinal drugs market size is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%. The change in the gastrointestinal drugs market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The GI drugs market is expected to reach $105.51 billion in 2026 at a CAGR of 8.7%.

What is the Global Gastrointestinal Drugs Market?

The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce GI drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key GI diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors, Sucralfate, and Misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant.

Get a Sample of the global gastrointestinal drugs market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2136&&type=smp

What drives the Global Gastrointestinal Drugs Market?

The aging population profile of most countries will contribute to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, will contribute significantly to the growth of the market during the forecast period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This will lead to increased demand for pharmaceuticals products, significantly impacting market growth during this period.

Get the full global gastrointestinal drugs industry report here

Global Gastrointestinal Drugs Market Segments
The global GI drugs market is segmented:
By Type: Antacids, Antiulcerants, Vitamin and Minerals, Antiobesity, Antiemetics and Antinauseants, Antidiarrheals
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others
By Route of Administration: Oral, Parenteral, Others
By Drug Classification: Branded Drugs, Generic Drugs
By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs
By Geography: The regions covered in the gastrointestinal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Gastrointestinal Drugs Global Market Report 2022provides market size and growth forecasts for the global gastrointestinal drugs market, global gastrointestinal drugs market share, gastrointestinal drugs market segments and geographies, gastrointestinal drugs market competitive landscape including leading competitors’ revenues, profiles and market shares. The gastrointestinal drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Global Gastrointestinal Drugs Industry Playersinclude Takeda Pharmaceuticals, Bayer AG, Abbott Laboratories, Otsuka Holdings Co ltd, Johnson & Johnson, Reckitt Benckiser Group plc, Bausch Health Companies Inc., Sanofi S.A, Procter & Gamble and Daiichi Sankyo Company. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.